TSOI (Therapeutic Solutions International) ROC %: -198.26% (As of Sep. 2024)


What is Therapeutic Solutions International ROC %?

Therapeutic Solutions International TSOI -99.00% ROC % is -198.26% as of Sep. 2024.

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Therapeutic Solutions International's annualized return on capital (ROC %) for the quarter that ended in Sep. 2024 was -198.26%.

As of today (2026-07-04), Therapeutic Solutions International's WACC % is 0.00%. Therapeutic Solutions International's ROC % is 0.00% (calculated using TTM income statement data). Therapeutic Solutions International earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Therapeutic Solutions International  (OTCPK:TSOI) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Therapeutic Solutions International's WACC % is 0.00%. Therapeutic Solutions International's ROC % is 0.00% (calculated using TTM income statement data). Therapeutic Solutions International earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Therapeutic Solutions International ROC % Related Terms


Therapeutic Solutions International ROC % Historical Data

* Premium members only.

The historical data trend for Therapeutic Solutions International's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therapeutic Solutions International ROC % Chart

Therapeutic Solutions International Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -76.95 -109.53 -118.18 -96.93 -45.50

Therapeutic Solutions International Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
ROC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -42.66 -52.25 -65.07 -40.06 -198.26

Therapeutic Solutions International ROC % Calculation

Therapeutic Solutions International's annualized Return on Capital (ROC %) for the fiscal year that ended in Dec. 2023 is calculated as:

ROC % (A: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2022 ) + Invested Capital (A: Dec. 2023 ))/ count )
=-1.986 * ( 1 - 0% )/( (4.565 + 4.165)/ 2 )
=-1.986/4.365
=-45.50 %

where

Therapeutic Solutions International's annualized Return on Capital (ROC %) for the quarter that ended in Sep. 2024 is calculated as:

ROC % (Q: Sep. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2024 ) + Invested Capital (Q: Sep. 2024 ))/ count )
=-7.84 * ( 1 - 0% )/( (3.958 + 3.951)/ 2 )
=-7.84/3.9545
=-198.26 %

where

Note: The Operating Income data used here is four times the quarterly (Sep. 2024) data. The tax rate is limited to between 0% and 100%.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROC % →
What does a ROC % of -198.26% mean?
Therapeutic Solutions International (TSOI) has a ROC % of -198.26% as of Sep. 2024. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Therapeutic Solutions International and its competitors.
Is Therapeutic Solutions International's ROC % too high?
Therapeutic Solutions International's current ROC % is -198.26%.
How does Therapeutic Solutions International's ROC % compare to BPTH and RGBP?
Therapeutic Solutions International's ROC % of -198.26% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC % for a Biotechnology company?
A good ROC % depends on the Biotechnology industry context. However, ROC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC % mean?
A high ROC % can signal that a stock is expensive relative to its fundamentals. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Therapeutic Solutions International and its competitors. Therapeutic Solutions International's current ROC % is -198.26%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Therapeutic Solutions International stock overvalued right now?
Therapeutic Solutions International (TSOI) has a current ROC % of -198.26%. The current ROC % is -198.26%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC % calculated?
ROC % is calculated from a company's financial statements. For Therapeutic Solutions International (TSOI), the current ROC % is -198.26% as of Sep. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Therapeutic Solutions International Business Description

Address 701 Wild Rose Lane, Elk City, ID, USA, 83525
Therapeutic Solutions International Inc focuses on immune modulation for the treatment of several specific diseases. It is engaged in developing a range of immune-modulatory agents to target certain cancers, improve maternal and fetal health, fight periodontal disease, and for daily health. The business divisions of the company are Nutraceutical Division which produces nutraceuticals. Its current product, QuadraMune, is a patented synergistic blend of pterostilbene, sulforaphane, epigallocatechingallate, and thymoquionone. Cellular Division obtained exclusive rights to a patented adult stem cell for the development of therapeutics in the area of chronic traumatic encephalopathy and traumatic brain injury and Lung Pathology.